Navigation Links
GenOdyssee Receives Broad Product Applications Protection in EU for Founding Natural Evolution Technology
Date:10/24/2008

ed with HCV type 3 (genotype 3a) virus, in which GEA007.1 reduced

HCV RNA to levels 3-4 fold lower than IFN alpha 2 drugs.

- Stronger anti-HCV activity in vitro in the HCV genotype 1b

subgenomic replicon assay (BM4-5 cells) as compared to IFN alpha 2.

GEA007.1 exhibits a 7 fold superior inhibitory activity on HCV genotype

1b RNA synthesis compared to IFN alpha 2.

- Viral clearance of HCV genotype 1b replicon subgenome was

obtained in BM4-5 cells after long-term administration (20 days) of

GEA007.1, as evidenced by elimination of HCV genotype 1b RNA (both

strands) replicon genome. In contrast, HCV genotype 1b RNA (both strands)

was still apparent in cells treated with IFN alpha 2 in same conditions.

- No rebound of HCV genotype 1 replication after cessation of

GEA007.1 treatment. HCV subgenomic RNA remained undetectable after 5

passages post-treatment in GEA007.1 treated cells, whereas a low amount

of positive strand HCV subgenomic RNA was maintained in IFN alpha 2

treated cells.

- Similar safety pharmacology in rhesus monkeys (Macaca

mulatta) to IFN alpha 2.

- Importantly, GEA007.1 is a natural human protein, which

means it is already functional and tolerated in man.

CONTACT: Dr. Jean-Louis Escary, CEO

Tel: +33(0)616-416-857

Email: escary@genodyssee.com


'/>"/>
SOURCE GenOdyssee SA
Copyright©2008 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2 3 4

Related biology technology :

1. Spherix Receives Nasdaq Letter Extending Minimum Bid Price Compliance Period
2. Alfacell Receives Going Concern Audit Opinion
3. Peregrine Pharmaceuticals Receives Additional Time to Regain Compliance With NASDAQs Minimum Bid Price Rule
4. NanoVibronix Receives FDA Clearance for its PainShield(TM) MD Device
5. PAREXEL Corporate Vice President Dr. Alberto Grignolo Receives Lifetime Achievement Award From Good Clinical Practice Journal
6. Medivation Receives Corporate Achievement Award From Huntingtons Disease Society of America
7. Bolder BioTechnology Receives $1.6 million NIH Grant to Continue Development of Multiple Sclerosis Drug
8. BIO Ventures for Global Health Receives $7 Million Grant from Gates Foundation to Engage Biotechnology in the Fight Against Neglected Diseases of the Developing World
9. Althea Technologies Receives Fast Growth Honors: Deloitte Technology Fast 50 and San Diego Business Journal Fast 100 Awards for the Fifth Consecutive Year
10. POET Receives Additional $76 Million in Federal Funding For Commercialization of Cellulosic Ethanol
11. Imaging Diagnostic Systems Receives its First Order for its CT Laser Mammography System for Israel
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Biology Technology:ATS Medical Announces CE Mark Approval for the ATS 3f Enable Bioprosthesis 2ATS Medical Announces CE Mark Approval for the ATS 3f Enable Bioprosthesis 3ATS Medical Announces CE Mark Approval for the ATS 3f Enable Bioprosthesis 4Publication in Neuropsychopharmacology Confirms CeNeRx's Novel RIMA Antidepressant TriRima(TM) Selectively and Reversibly Inhibits MAO-A 2Publication in Neuropsychopharmacology Confirms CeNeRx's Novel RIMA Antidepressant TriRima(TM) Selectively and Reversibly Inhibits MAO-A 3Publication in Neuropsychopharmacology Confirms CeNeRx's Novel RIMA Antidepressant TriRima(TM) Selectively and Reversibly Inhibits MAO-A 4BioLife Solutions Announces Custom cGMP Manufacturing & License Agreement 2BioLife Solutions Announces Custom cGMP Manufacturing & License Agreement 3Breakthrough TriPollar Technology- the Most Advanced Anti-Aging Solution- to Launch into High Growth Brazilian Market for Aesthetic Procedures 2Breakthrough TriPollar Technology- the Most Advanced Anti-Aging Solution- to Launch into High Growth Brazilian Market for Aesthetic Procedures 3
Other Biology Technology:Women's Surgery Recorded for the First Time on '4K' Digital Cinema is Presented at the AAGL Congress 2CryoLife's Fully Diluted Earnings Per Share Increased 71 Percent to $0.12 in Third quarter of 2008 from $0.07 in Third quarter of 2007 2CryoLife's Fully Diluted Earnings Per Share Increased 71 Percent to $0.12 in Third quarter of 2008 from $0.07 in Third quarter of 2007 3CryoLife's Fully Diluted Earnings Per Share Increased 71 Percent to $0.12 in Third quarter of 2008 from $0.07 in Third quarter of 2007 4CryoLife's Fully Diluted Earnings Per Share Increased 71 Percent to $0.12 in Third quarter of 2008 from $0.07 in Third quarter of 2007 5CryoLife's Fully Diluted Earnings Per Share Increased 71 Percent to $0.12 in Third quarter of 2008 from $0.07 in Third quarter of 2007 6CryoLife's Fully Diluted Earnings Per Share Increased 71 Percent to $0.12 in Third quarter of 2008 from $0.07 in Third quarter of 2007 7CryoLife's Fully Diluted Earnings Per Share Increased 71 Percent to $0.12 in Third quarter of 2008 from $0.07 in Third quarter of 2007 8CryoLife's Fully Diluted Earnings Per Share Increased 71 Percent to $0.12 in Third quarter of 2008 from $0.07 in Third quarter of 2007 9CryoLife's Fully Diluted Earnings Per Share Increased 71 Percent to $0.12 in Third quarter of 2008 from $0.07 in Third quarter of 2007 10CryoLife's Fully Diluted Earnings Per Share Increased 71 Percent to $0.12 in Third quarter of 2008 from $0.07 in Third quarter of 2007 11Mylan Reports Adjusted Diluted EPS of $0.23 for the Quarter Ended Sept. 30, 2008 2Mylan Reports Adjusted Diluted EPS of $0.23 for the Quarter Ended Sept. 30, 2008 3Mylan Reports Adjusted Diluted EPS of $0.23 for the Quarter Ended Sept. 30, 2008 4Mylan Reports Adjusted Diluted EPS of $0.23 for the Quarter Ended Sept. 30, 2008 5Mylan Reports Adjusted Diluted EPS of $0.23 for the Quarter Ended Sept. 30, 2008 6Mylan Reports Adjusted Diluted EPS of $0.23 for the Quarter Ended Sept. 30, 2008 7Mylan Reports Adjusted Diluted EPS of $0.23 for the Quarter Ended Sept. 30, 2008 8Mylan Reports Adjusted Diluted EPS of $0.23 for the Quarter Ended Sept. 30, 2008 9Mylan Reports Adjusted Diluted EPS of $0.23 for the Quarter Ended Sept. 30, 2008 10Mylan Reports Adjusted Diluted EPS of $0.23 for the Quarter Ended Sept. 30, 2008 11Mylan Reports Adjusted Diluted EPS of $0.23 for the Quarter Ended Sept. 30, 2008 12Mylan Reports Adjusted Diluted EPS of $0.23 for the Quarter Ended Sept. 30, 2008 13Mylan Reports Adjusted Diluted EPS of $0.23 for the Quarter Ended Sept. 30, 2008 14